Cardiovascular Diseases Clinical Trial
To evaluate if use of an implantable cardiac defibrillator (ICD) results in reduction in total mortality, when compared with conventional pharmacological therapy, in patients resuscitated from sudden cardiac death who are otherwise at very high risk of mortality from arrhythmic causes.
BACKGROUND:
Sudden cardiac death is believed to account for a substantial proportion of deaths in
patients with evidence of cardiovascular disease. The exact proportion of cardiac deaths
that are classified as being sudden varies depending on the population, the underlying
disease, and the definition of sudden death. Various estimates suggest that about 500,000
sudden cardiac deaths occur annually in the United States alone. The majority of sudden
cardiac deaths are thought to be due to ventricular fibrillation (VF) or tachycardia (VT).
The commonest approach to preventing sudden cardiac death has been by the use of drugs that
suppress ventricular ectopy. The rational for this approach is based upon an association
between the presence or frequency of ventricular arrhythmia and subsequent mortality in
several studies. None of the randomized controlled studies of numerous 'classical'
antiarrhythmic agents (other than beta-blockers, which have only a modest effect on
arrhythmia suppression) have demonstrated a reduction in sudden or non-sudden cardiac
mortality. Indeed, in the recent Cardiac Arrhythmia Suppression Trial (CAST), two class Ic
anti-arrhythmic agents demonstrated a 2.5 fold increase in the risk of sudden and non-sudden
cardiac deaths despite excellent suppression of ventricular arrhythmia.
Given the disappointing results of most pharmacologic approaches to preventing sudden death,
many investigators have turned to non-pharmacologic approaches such as surgery (endocardial
resection, stellate ganglionectomy) or the implantation of devices that recognize VT or VF
and deliver a shock. The greatest interest has been generated by work on the implantable
cardiac defibrillator.
The study was reviewed by an ad hoc working group, the Clinical Applications and Prevention
Advisory Committee, and several members of the Cardiology Advisory Committee prior to review
and approval by the National Heart, Lung, and Blood Advisory Council in September 1991. The
Request for Proposals was released in February 1992.
DESIGN NARRATIVE:
At approximately 28 clinical sites, patients with ventricular tachycardia or ventricular
fibrillation were screened. Those with ventricular fibrillation or serious ventricular
tachycardia were entered into a registry for long-term mortality follow-up using the
National Death Index. Patients with the prospect of long-term benefit from an ICD and/or
antiarrhythmic drug therapy and without exclusions to an ICD or to amiodarone and without a
transient or correctible cause of the index event were entered into the trial.
Patients meeting the criteria were randomized to treatment with an ICD or treatment with
antiarrhythmic drug therapy. Allocation was stratified by clinical site and index
arrhythmia, either ventricular fibrillation or ventricular tachycardia. Patients assigned to
the antiarrhythmic drug therapy and without contraindications to sotalol underwent
subrandomization to either empiric amiodarone or sotalol, the latter treatment guided by
either ambulatory monitoring or electrophysiologic testing. Patients who, after
subrandomization, had low levels (less than 30 beats per hour) of ventricular ectopic beats
and no inducible ventricular arrhythmias at electrophysiologic study were not treated with
sotalol and instead received empiric amiodarone. The AVID protocol allowed usual clinical
practice but restricted interventions to state-of-the art ICD devices and first-line
antiarrhythmic agents to amiodarone and sotalol. Patients who could not take amiodarone were
not included in the trial. The protocol encouraged the use of concurrent drugs such as
angiotensin-converting enzyme inhibitors, aspirin, and beta-blockers when appropriate,
administered before randomization and maintained throughout the study. The primary endpoint
was total mortality. Secondary endpoints were cost of health care and quality of life.
Nonlethal events such as ICD shock, sustained arrhythmia, or syncope were tabulated.
Patients were followed every three months for assessment of secondary endpoints, to record
therapies delivered by the ICD and potential adverse effects of the ICD, and to assess
compliance and potential adverse symptoms in patients treated with antiarrhythmic drugs. A
12-lead electrocardiogram was obtained every six months, and appropriate laboratory and
pulmonary tests were performed at six and eighteen months on patients receiving amiodarone.
The average follow-up was expected to be 2.6 years. Analysis was done by intention-to-treat.
The outcome of primary interest in the subrandomization between sotalol and amiodarone was
the time to withdrawal from assigned therapy.
After a review of the data by the Data and Safety Monitoring Board, the AVID study was
stopped early on April 7, 1997 because of the findings that after one year, patients in the
defibrillator group experienced a nearly 38 percent reduction in deaths compared to the
group of patients taking an antiarrhythmic drug. The defibrillator group had about a 25
percent reduction in deaths in years two and three.
;
Allocation: Randomized, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|